Table 1.
The change in human renal hemodynamics after long-term vasodilator treatment for hypertension.
| Vasodilators | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug | References | RBF/RPF | Pglom | GFR | FF | RVR | Duration (weeks) | Participant number |
| Prazosin | Koshy et al., 1977 | = | = | 8 | 14 | |||
| Preston et al., 1979; Warren et al., 1981 | = | = | = | RA: 
|
4 | 10 males† | ||
| RE: = | ||||||||
| RV: = | ||||||||
| O'Connor et al., 1979 | = | = | = | 4 | 12 males | |||
| Bauer et al., 1984b | = | = | = | |
3–6 | 14 | ||
| Anderton et al., 1994 | = | |
10 | 14 | ||||
| Indoramin | Bauer et al., 1984a | = | = | = | |
3–6 | 11 males | |
| Clonidine | Cohen et al., 1979 | = | = | = | |
4 | 13 | |
| Thananopavarn et al., 1982 | = | = | 12 | 16 | ||||
| Golub et al., 1983 | = | = | 1 | 16 | ||||
| = | = | 12 | As above | |||||
| Moxonidine | Fauvel et al., 1998 | = | = | = | 4 | 20 | ||
| α-Methyldopa | Weil et al., 1963 | = | = | 1–3 | 9 | |||
| Mohammed et al., 1968 | = | = | |
1 | 8 | |||
| Grabie et al., 1980 | = | |
1 | 8 | ||||
| Verapamil | Leonetti et al., 1980 | = | 1.5 | 12 | ||||
| Sorensen et al., 1985 | = | = | = | 6 | 11 | |||
| Katzman et al., 1990 | |
= | = | 8 | 15 | |||
| Diltiazem | Isshiki et al., 1987 |  |
|
= | |
RA:
|
52 | 7 |
| RE:
|
||||||||
| Sunderrajan et al., 1987 | = | = | = | |
8 | 18 | ||
| Manidipine | Ott et al., 2013 | = | = | = | RA:
|
4 | 54 | |
| RE:
|
||||||||
| Nicardipine | Smith et al., 1987 | = | = | |
6 | 6 | ||
| Kimura et al., 1988 | = | 1 | 8 | |||||
| Kimura et al., 1991a | = | = | = | RA:
|
1 | 8 | ||
| RE: = | ||||||||
| Nitrendipine | Thananopavarn et al., 1984 | = | = | 2 | 10 males | |||
| Scaglione et al., 1992 | |
= | = | |
8 | 13 | ||
| Isradipine | Persson et al., 1989 | |
= | |
9 | 20 males | ||
| Amlodipine | Ranieri et al., 1994 | = | = | = | 12 | 18 | ||
| Inigo et al., 2001 | = | |
|
= | RA: *
|
6 | 17 (renal transplant recipients) | |
| RE: = | ||||||||
| Delles et al., 2003 | = | |
|
|
RA:
|
8 | 29 | |
| RE:
|
||||||||
| Ott et al., 2013 | = | |
= | RA:
|
4 | 50 | ||
| RE:
|
||||||||
| Nifedipine | Olivari et al., 1979 | = | 3 | 27 | ||||
| Guazzi et al., 1984 | = | 1 | 14 | |||||
| Reams et al., 1988 | |
|
= | |
4 | 26 | ||
Participants are individuals with essential hypertension unless otherwise specified. RBF/RPF, renal blood flow/renal plasma flow; GFR, glomerular filtration rate; FF, filtration fraction; RVR, renal vascular resistance; , significant decrease from control; , significant increase from control; =, no significant change from control; RA, afferent arteriolar resistance; RE, efferent arteriolar resistance.
*
Discrepancy between reported result in the text and in the results table—mistake in decimal point placement in results table assumed (Inigo et al., 2001).
†
Identical data in two publications, one stating n = 10 and one n = 12.